A phase I/II pharmacokinetics/pharmacodynamics study of irinotecan combined with S−1 for recurrent/metastatic breast cancer in patients with selected UGT1A1 genotypes (the JBCRG‐M01 study)

S‐1 and irinotecan combination is attractive for breast cancer refractory to anthracyclines and taxanes. Patients with advanced human epidermal growth factor receptor 2 (HER2)‐negative breast cancer previously treated with anthracyclines and taxanes were eligible. Patients with brain metastases and...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer Med
Main Authors: Ishiguro, Hiroshi, Saji, Shigehira, Nomura, Shogo, Tanaka, Sunao, Ueno, Takayuki, Onoue, Masahide, Iwata, Hiroji, Yamanaka, Takeharu, Sasaki, Yasutsuna, Toi, Masakazu
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2017
Assuntos:
Clinical Cancer Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5727322/
https://ncbi.nlm.nih.gov/pubmed/29131533
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.1258
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares